ADVANCING IMMUNOTHERAPY IN OVARIAN CANCER: CHALLENGES AND OPPORTUNITIES

Esra Hassan Abd Ali*

Ovarian cancer is still one of the deadliest gynecological cancers because of its late diagnosis and high rate of recurrence after standard treatments. Immunotherapy is a promising novelty in the battle against different forms of cancer; however, its use on ovarian cancer has evoked both struggles and opportunities at the same time. This review intends to elaborate on the latest developments in immunotherapy for ovarian cancer with special reference of tumor microenvironment, immune checkpoints and emerging approaches that are shaping treatment paradigms. So, we will focus on the biological basis behind ovarian cancer as a subject for immunotherapy approaches, we will also look into the possible developments in new combination therapies, personalized medicine approaches and vaccine development that seem to show promise during preclinical and early clinical trials. By reviewing the most recent research findings and data from clinical trials, this paper will give a broad overview of how promising immunotherapy may be in improving outcomes for patients with ovarian cancer while also acknowledging that there is still much work to do when it comes to incorporating these therapies into standard practices. Through this integration of present understanding and future prospects, we strive to map a path to address current hindrances for realizing the full benefits of immunotherapy in incorporating ovarian cancer treatment.